Channel Therapeutics Corporation
CHRO · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $8,071 | $87,017 | $36,430 |
| - Cash | $14,203 | $59 | $131 | $513 |
| + Debt | $2,849 | $2,305 | $2,503 | $2,186 |
| Enterprise Value | – | $10,316 | $89,389 | $38,103 |
| Revenue | $7,406 | $0 | $0 | $933 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | -$194 | $467 |
| % Margin | 0% | – | – | 50% |
| EBITDA | -$14,383 | -$3,230 | -$0 | -$2,218 |
| % Margin | -194.2% | – | – | -237.6% |
| Net Income | -$16,238 | -$3,449 | -$1,968 | -$1,927 |
| % Margin | -219.3% | – | – | -206.5% |
| EPS Diluted | -5.3 | -5.38 | -0.32 | -0.34 |
| % Growth | 1.5% | -1,581.2% | 5.9% | – |
| Operating Cash Flow | -$15,259 | -$447 | -$632 | -$670 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$15,259 | -$447 | -$632 | -$670 |